Abstract:Aim: Recombiant human telomerase reverse transcriptase (hTERT)-human IL-18(hIL18) was constructed to investigate its expression and biological function in eukaryotic cells. DCs transfected with hTERT-IL18 acquired stronger telomerase activity and were able to elicit an hTERT-specific cytotoxic T lymphocyte CTL response in vitro.Methods: hIL-18 gene fragment was amplified by Polymerase chain reaction (PCR) and TA cloned. The hIL18 gene was then subcloned into eukaryotic expression vector pcDNA3.1(+) containing human TERM via a linker. The sequence of gene fusion was confirmed using both restrictive enzyme digestion and DNA sequencer. The expression vector with gene fusion was transfected into 3T3 cell line with Lipofectamine 2000. ELISA, Western blot, immunofluorescence stain were performed to determine the expression properties of hTERT-hIL18 in 3T3 cells. Its biological effect on the anti-apoptosis was measured by Flow cytometry and its effect on INF-gamma expression was determined using ELISA. After preparation of dendritic cells, hTERT-hIL18, hTERT, hIL-18 expression vectors were transfected into DCs respectively by electroporation to generate hTERT-specific DCs lines. The peripheral blood mononuclear cells PBMCs were stimulated with different DCs lines to create specific CTL. The response of target cell (leukemia cell line-K562 cell) to hTERT-specific CTL was evaluated by LDH release assay.Results: The human IL-18 gene fragment was amplified from the human mononuclear cells and was inserted into pcDNA3.1(+)/hTERT vector successfully. The correct sequence was proved by both restrictive enzyme digestion and sequencing. The correct open reading frame was also verified. Fusion protein of hTERT-hIL18 was effectively expressed in eukaryotic cells, which was detected by both Western-blotting and immunofluorescence stain. The expressed recombinant fusion protein induced similar levels of INF-gamma to that of native IL-18 protein. FCM assay showed that the transfected fusion protein inhibited the apoptosis, which was consistent with the effects of hTERT as a universal tumor associated antigen. CTL assay shows that hTERT-hIL18 and hTERT gene-transfected DCs stimulated T-cell responses that recognized and lysed tumor target cells of high hTERT expression, whereas DCs transfected with hIL-18 gene didn't induced the response of tumor targets lyses.Conclusion: The Recombinant hTERT-hIL18 fusion protein had both biological activity of hTERT and hIL-18, indicating that this rationally designed protein can be further developed as novel tumor therapeutics. DCs transfected with hTERT-IL18 gene were capable of eliciting a stronger hTERT-specific CTL response in vitro.

Myeloid Dendritic Cells Loaded with Dendritic Tandem Multiple Antigenic Telomerase Reverse Transcriptase (htert) Epitope Peptides: A Potentially Promising Tumor Vaccine

Human Telomerase Reverse Transcriptase-Specific T-helper Responses Induced by Promiscuous Major Histocompatibility Complex Class II-restricted Epitopes.

A Modified HLA-A*0201-restricted CTL Epitope from Human Oncoprotein (hpebp4) Induces More Efficient Antitumor Responses

In vitro anti-tumor immune response induced by dendritic cells transfected with hTERT recombinant adenovirus.

Enhanced Antitumor Effect Against Human Telomerase Reverse Transcriptase (Htert) By Vaccination With Chemotactic-Htert Gene-Modified Tumor Cell And The Combination With Anti-4-1bb Monoclonal Antibodies

Prediction and identification of HLA-A0201 restricted CTL epitopes derived from human telomerase reverse transcriptase antigen

Heparanase Epitope Peptide-Pulsed DCs Elicit Immune Responses Against Various Tumors in Vitro

Construction of Expression Vector of Htert- Hil18 Fusion Gene and Induction of Cytotoxic T Lymphocyte Response Against Htert.

Identification of a New Cytotoxic T-cell Epitope P675 of Human Telomerase Reverse Transcriptase.

Cancer Therapeutic Vaccines Targeting Htert-Derived T-cell Epitope Peptide: Advances in Researches

Multiple antigenic peptides of human heparanase elicit a much more potent immune response against tumors.

Induction of anti-tumour immunity by dendritic cells transduced with hTERT recombinant adenovirus in mice.

EpCAM peptide-primed dendritic cell vaccination confers significant anti-tumor immunity in hepatocellular carcinoma cells

Targeting pan-tumor antigens to activating Fcγ receptors generates a novel dendritic cell tumor vaccine

HLA-A2–Restricted Cytotoxic T Lymphocyte Epitopes from Human Heparanase as Novel Targets for Broad-Spectrum Tumor Immunotherapy

Effective antitumor immunity against murine gliomas using dendritic cells transduced with hTERTC27 recombinant adenovirus.

Cytotoxic T Lymphocyte Epitopes from Human Heparanase Can Elicit a Potent Anti-Tumor Immune Response in Mice

Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines

Optimized mobilization of MHC class I- and II- restricted immunity by dendritic cell vaccine potentiates cancer therapy

Induction of Anti-Tumor Immunity by Dendritic Cells Pulsed with an Endoplasmic Reticulum Retrieval Signal Modifies Heparanase Epitope in Mice.

Synthetic Tumor-Specific Antigenic Peptides with a Strong Affinity to HLA-A2 Elicit Anti-Breast Cancer Immune Response Through Activating CD8+ T Cells